In 2013, Google announced it would attempt to understand and ultimately slow aging through a company called Calico, a moonshot effort that would absorb at least $3.5 billion in funding, spawn ...

Calico ignited the race by drug companies to find treatments for aging-related diseases. An ALS-fighting drug from Calico Life Sciences LLC — the Alphabet-backed anti-aging company founded by ...

Fosigotifator, an amyotrophic lateral sclerosis drug developed by Calico Life Sciences, a biotech company backed by Google's parent company Alphabet, failed to meet its primary endpoint, according ...

AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all taken a hit. Massachusetts General Hospital found neither AbbVie and ...

In studies by Massachusetts General Hospital, an AbbVie-Calico collaborative drug and Denali Therapeutics' own drug failed to meet endpoints for treating amyotrophic lateral sclerosis, more widely ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A study of ...

The logo of Calico is seen on a screen. In the background there is the logo of Alphabet. Alphabet is the mother company of Google. Google’s (GOOGL) anti-aging company Calico released ...

The first data have now emerged from a drug Calico developed. It failed. The pill, known as fosigotifator, was not designed to slow aging itself.

The investigational oral therapies DNL343 and fosigotifator didn’t significantly slow disease progression in people with amyotrophic lateral sclerosis (ALS) compared with a placebo, and therefore ...

Fosigotifator is under clinical development by Calico Life Sciences and currently in Phase II for Unspecified Central Nervous System Disorders. According to GlobalData, Phase II drugs for Unspecified ...